Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Thompson, Mark G. ; Burgess, Jefferey L. ; Naleway, Allison L. ; Tyner, Harmony L. ; Yoon, Sarang K. ; Meece, Jennifer ; Olsho, Lauren E.W. ; Caban-Martinez, Alberto J. ; Fowlkes, Ashley ; Lutrick, Karen ; Kuntz, Jennifer L. ; Dunnigan, Kayan ; Odean, Marilyn J. ; Hegmann, Kurt T. ; Stefanski, Elisha ; Edwards, Laura J. ; Schaefer-Solle, Natasha ; Grant, Lauren ; Ellingson, Katherine ; Groom, Holly C. ; Zunie, Tnelda ; Thiese, Matthew S. ; Ivacic, Lynn ; Wesley, Meredith G. ; Lamberte, Julie Mayo ; Sun, Xiaoxiao ; Smith, Michael E. ; Phillips, Andrew L. ; Groover, Kimberly D. ; Yoo, Young M. ; Gerald, Joe ; Brown, Rachel T. ; Herring, Meghan K. ; Joseph, Gregory ; Beitel, Shawn ; Morrill, Tyler C. ; Mak, Josephine ; Rivers, Patrick ; Harris, Katherine M. ; Hunt, Danielle R. ; Arvay, Melissa L. ; Kutty, Preeta ; Fry, Alicia M. ; Gaglani, Manjusha
• Description:
  Messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines have been shown to be effective in preventing symptomatic COVID-19 in randomized placebo-controlled Phase III trials (1,2); however, the benefits of these vaccines for preventing asymptomatic and symptomatic SARS-CoV-2 (the Virus that causes COVID-19) infection, particularly when administered in real-world conditions, is less well understood. Using prospective cohorts of health care personnel, first responders, and other essential and frontline workers* in eight U.S. locations during December 14, 2020-March 13, 2021, CDC routinely tested for SARS-CoV-2 infections every week regardless of symptom status and at the onset of symptoms consistent with COVID-19-associated illness. Among 3,950 participants with no previous laboratory documentation of SARS-CoV-2 infection, 2,479 (62.8%) received both recommended mRNA doses and 477 (12.1%) received only one dose of mRNA vaccine.| Among unvaccinated participants, 1.38 SARS-CoV-2 infections were confirmed by reverse transcription-polymerase chain reaction (RT-PCR) per 1,000 person-days.| In contrast, among fully immunized (≥14 days after second dose) persons, 0.04 infections per 1,000 person-days were reported, and among partially immunized (≥14 days after first dose and before second dose) persons, 0.19 infections per 1,000 person-days were reported. Estimated mRNA vaccine effectiveness for Prevention of infection, adjusted for study site, was 90% for full immunization and 80% for partial immunization. These findings indicate that authorized mRNA COVID-19 vaccines are effective for preventing SARS-CoV-2 infection, regardless of symptom status, among working-age adults in real-world conditions. COVID-19 vaccination is recommended for all eligible persons.
• Subjects:
  Adolescent Adult CoronaVirus Infections COVID-19 COVID-19 Nucleic Acid Testing COVID-19 Vaccines Emergency Responders Female Health Personnel Humans Male Middle Aged Occupational Diseases Occupations Prospective Studies Vaccines, Synthetic Young Adult

  More +
• Source:
  MMWR Morbidity Mortal Weekly Rep. 70(13):495-500
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  33793460
• Pubmed Central ID:
  PMC8022879
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  6 pdf pages
• Volume:
  70
• Issue:
  13
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:82713f02405d05c3f5c1c8d7db11177156c3e58aba04965a724bd648f9b66d67ec33edf02b24731184ed076765e4df7cf92d945ea1dc20f3adebd4877229ee92
• Download URL:
  https://stacks.cdc.gov/view/cdc/105169/cdc_105169_DS1.pdf
• File Type:
  [PDF - 118.85 KB ]